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Lis
Yo
MaBACKGROUND Immature platelets are less responsive to the effects of antiplatelet drugs and contain messenger
ribonucleic acid that is translationally active. They can be measured easily using an automated hematoanalyzer and
reported as part of the complete blood count.
OBJECTIVES The purpose of this study was to determine the prognostic signiﬁcance of elevated immature platelet
count (IPC) in patients with coronary artery disease (CAD).
METHODS In this prospective cohort study in patients with CAD, patients underwent IPC measurement and were then
followed up for the composite endpoint of major adverse cardiovascular events (MACE), deﬁned as a composite of
all-cause mortality, myocardial infarction, unplanned revascularization, or hospitalization for angina. For the purposes of
analysis, patients were stratiﬁed into tertiles of IPC.
RESULTS Eighty-nine patients were followed up for a median of 31 months. Stratiﬁcation to the high IPC tertile was
associated with higher rates ofMACE compared with the intermediate and low tertiles (60%vs. 24% vs. 16%, respectively;
p < 0.001). Time-dependent receiver-operating characteristic analysis revealed that an IPC level $7,632 platelets/ml was
70.7% sensitive and 82.1% speciﬁc for MACE. After adjustment for age, admission diagnosis, index revascularization, heart
failure, smoking, hematocrit, and baseline platelet count, patients with an IPC level$7,632 platelets/ml were more likely to
experience a MACE (hazard ratio: 4.65; 95% conﬁdence interval: 1.78 to 12.16; p < 0.002).
CONCLUSIONS IPC is a novel biomarker for MACE risk stratiﬁcation in patients with CAD. Future studies should
focus on the utilization of this marker for individualized antiplatelet therapy. (J Am Coll Cardiol 2014;64:2122–9)
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not homogeneous; different subpopulations of plate-
lets can be categorized according to their activation
patterns in response to different agonists (3). Imma-
ture platelets, also termed reticulated platelets (RPs)
as they are analogous to erythroid reticulocytes,
comprise the youngest component of the circulating
platelet pool, and appear to participate most actively
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AB BR E V I A T I O N S
AND ACRONYM S
AUC = area under the curve
CAD = coronary artery disease
IPC = immature platelet count
IPF = immature platelet
fraction
MACE = major adverse
cardiovascular event(s)
NSTEMI = non-ST-segment
elevation myocardial infarction
ROC = receiver-operating
characteristic
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2123advance was identifying RPs with ﬂow cytometry af-
ter staining blood specimens with thiazole orange
(13,14). However, ﬂow cytometry is a time-consuming
and costly procedure without a standardized protocol
and not well suited for rapid screening in patients in
clinical practice. More recently, newer assay tech-
niques have been developed to allow for automated
immature platelet determination as part of the stan-
dard complete blood count (15). The aim of the cur-
rent study was to evaluate the ability of the
automated method for immature platelet detection to
further stratify patients with coronary artery disease
(CAD) according to their risk for clinical outcomes.SEE PAGE 2130 RP = reticulated platelets
STEMI = ST-segment elevation
myocardial infarctionMETHODS
STUDY DESIGN. In this prospective cohort study, the
inclusion criteria were age $18 years, the ability to pro-
vide informed consent, diagnosis of CAD, and current
treatment with dual antiplatelet therapy (unless coro-
nary artery bypass graft [CABG] surgery was performed).
The study protocol was approved by the Houston
Methodist Hospital institutional review board, and all
patients provided written informed consent. Patients
were excluded if they had received any blood prod-
ucts within the 30 days before immature platelet
evaluation.
The primary study outcome was the occurrence of
major adverse cardiovascular events (MACE), deﬁned
as the composite endpoint of all-cause mortality,
MI (either ST-segment elevation myocardial infarction
[STEMI] or non-ST-segment elevation myocardial
infarction [NSTEMI]), unplanned revascularization,
or recurrent angina requiring hospitalization. Myo-
cardial infarction was deﬁned as symptoms suggestive
of myocardial ischemia (i.e., chest pain or discomfort)
associated with biochemical evidence of myocardial
necrosis, deﬁned as the level of cardiac troponin >5
times the upper limit of normal (16). Unplanned
revascularization was deﬁned as the need for coronary
revascularization that was not planned or staged at the
index hospitalization. Anginawas reported by patients
and was deﬁned as discomfort, pain, and/or tightness
in the chest, jaw, shoulder, back, and/or arm that was
aggravated by exertion and relieved by nitroglycerin or
rest (17). To ensure the accuracy of the diagnosis of
angina, categorization of an angina episode as an event
required the patient to have had an overnight stay in
the hospital for the evaluation of anginal symptoms.
Patients were contacted between August and
October of 2013 for the evaluation of the occurrence
of the primary outcome. Follow-up was conducted by
2 investigators who were blinded to the immatureplatelet count (IPC) results and who made
telephone calls to all of the patients or to
their families if a patient was deceased.
Follow-up ended at the time of the ﬁrst con-
tact with the patient or family.
IPC MEASUREMENT. Immature platelets
were measured with an automated hema-
toanalyzer (Sysmex 2100 XE, Sysmex America
Inc., Mundelein, Illinois) that uses ﬂuores-
cent dyes containing polymethine and oxa-
zine. Both dyes penetrate the cell membrane
and stain the RNA in erythrocytes and leu-
kocytes as well as platelets. Stained cells are
then sorted as they pass through a beam of
light created by a semiconductor laser diode.
After measurements of cell volume (using
forward scatter light) and RNA content (using ﬂuo-
rescence intensity), the device provides scattergrams
using a proprietary nonadjustable software algo-
rithm with a preset gate (Sysmex IPF Master). This
system discriminates between mature and immature
platelets and reports the immature platelet fraction
(IPF). The IPC can then be determined by multiplying
IPF by the platelet count from the complete blood
count.
Immature platelet measurements were conducted
on enrollment. In patients who underwent revascu-
larization (either CABG or percutaneous coronary
intervention), IPC was evaluated within 72 h of the
index revascularization. In all other patients, IPC was
evaluated within 72 h of admission to the hospital.
TURBIDIMETRIC PLATELET AGGREGATION. Light
transmission aggregometry was used to measure
agonist-induced platelet aggregation. We collected
20 ml of whole blood in 0.32% sodium citrate (ﬁnal
concentration). The tubes were centrifuged immedi-
ately at 1,700 g for 6 min to prepare platelet-rich
plasma. The remaining whole blood fraction was
further centrifuged at 3,200 g for 15 min to separate
platelet-poor plasma. The platelet count in platelet-
rich plasma was standardized between 200 and
250  103 cells/ml. Platelet aggregation was induced
using 5 and 20 mM adenosine diphosphate (ADP) (ﬁnal
concentrations). The maximum aggregation achieved
during a 6-min period was used for analysis.
Aggregation was assessed after an adequate period
to ensure full antiplatelet effect (i.e., at least 6 h after
600 mg clopidogrel loading dose, at least 12 h after
300 mg clopidogrel loading dose, or long-term use of
clopidogrel 75 mg daily for at least 5 days).
STATISTICAL ANALYSIS. Categorical variables were
analyzed using the Fisher exact test. To evaluate the
differences between normally distributed continuous
TABLE 1 Baseline Demographics Stratiﬁed by MACE at Follow-Up
Total
(N ¼ 89)
MACE at Follow-Up
(þ)
(n ¼ 30)
()
(n ¼ 59) p Value
Demographics
Age, yrs 68.1  12.1 70  11 67.2  12.6 0.294
Male 57 (64%) 19 (63.3%) 38 (64.4%) 0.751
Ejection fraction, % 55 (39–60) 50 (31–60) 55 (40–60) 0.497
Medications at time of enrollment
Aspirin 83 (93.3%) 30 (100%) 53 (89.8%) 0.093
Clopidogrel 70 (78.7%) 26 (86.7%) 44 (74.6%) 0.275
Beta-blocker 85 (95.5%) 29 (96.7%) 56 (94.9%) 1.000
Statin 80 (89.9%) 29 (96.7%) 51 (86.4%) 0.263
Medical history at time of enrollment
Diabetes 37 (41.6%) 10 (33.3%) 27 (45.8%) 0.363
History of heart failure 29 (32.6%) 13 (43.3%) 16 (27.1%) 0.153
Hyperlipidemia 76 (85.4%) 28 (93.3%) 48 (81.4%) 0.205
Tobacco use 22 (24.7%) 5 (16.7%) 17 (28.8%) 0.299
Peripheral vascular
disease
12 (13.5%) 5 (16.7%) 7 (11.9%) 0.534
Stroke 10 (11.2%) 4 (13.3%) 6 (10.2%) 0.789
Hypertension 84 (94.4%) 30 (100%) 54 (91.5%) 0.163
Laboratory analysis at time of enrollment
WBC, x103 cell/ml 7.7 (6.1–9.2) 8.0 (6.1–9.1) 7.6 (6.1–9.2) 0.892
Hemoglobin, g/dl 11.3  2.1 11.1  2.5 11.3  1.9 0.765
RDW, ﬂ 46.6 (43.0–51.3) 48.0 (44.9–53.2) 45.2 (42.2–50.1) 0.020
Platelets, x 103 platelet/ml 180 (137–219) 197 (167–246) 179 (133–210) 0.117
BUN, mg/dl 20.0 (15.0–27.0) 20.0 (15.8–28.8) 19.0 (15.0–26.0) 0.581
Creatinine 1.0 (0.8–1.4) 1.0 (0.8–1.5) 1.0 (0.8–1.2) 0.976
Cardiac diagnosis at time of enrollment 0.797
Stable CAD 38 (42.7%) 13 (43.3%) 25 (42.4%)
STEMI 4 (4.5%) 2 (6.7%) 2 (3.4%)
Unstable angina/NSTEMI 47 (52.8%) 15 (50%) 32 (54.2%)
Revascularization/treatment strategy at time of enrollment 0.590
CABG 26 (29.2%) 7 (23.3%) 19 (32.2%)
Medical therapy only 33 (37.1%) 11 (36.7%) 22 (37.3%)
Stent 30 (33.7%) 12 (40%) 18 (30.5%)
Platelet assay results
IPF, % 4.3 (3.0–5.8) 5.3 (4.3–6.4) 3.7 (3.0–5.1) 0.007
IPC, platelets/ml 7,353
(4,860–11,154)
10,507
(7,166–13,482)
6,322
(4,730–8,250)
0.002
MPV, ﬂ 10.6  1.0 10.8  1.0 10.5  1.0 0.224
5M-ADP aggregation, % 43.8  19.3 45.9  18.7 42.4  19.8 0.542
20M-ADP aggregation, % 55.0 (42.0–65.5) 54.0 (37.2–67.5) 55.0 (47.0–63.0) 0.759
Values are mean  SD, n (%), or median (interquartile range).
ADP ¼ adenosine diphosphate; BUN ¼ blood urea nitrogen; CAD ¼ coronary artery disease; CABG ¼ coronary
artery bypass graft; IPC ¼ immature platelet count; IPF ¼ immature platelet fraction; MACE ¼ major adverse
cardiac event(s); MPV ¼ mean platelet volume; NSTEMI ¼ non-ST-segment elevation myocardial infarction;
RDW ¼ red blood cell distribution width; STEMI ¼ ST-segment elevation myocardial infarction; WBC ¼ white
blood cell.
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2124variables, the Student t test was used, and for
variables that were not normally distributed, we
employed the Wilcoxon rank sum test. Normality
was evaluated using the Shapiro-Wilk test, with
alpha # 0.05 as the threshold to reject the assumption
of normality. Time-dependent receiver-operating
characteristic (ROC) curve analysis was performed todetermine an IPC level that may have prognostic
signiﬁcance for MACE (18,19). The optimal cutoff was
considered as the point that maximized sensitivity
and speciﬁcity. Cox proportional hazards analysis was
used to analyze the relationship between elevated
IPC level and MACE. To evaluate the unadjusted
relationship between clinical outcomes and IPC level,
patients were stratiﬁed by IPC tertile. Following
this, either the log-rank test of the Kaplan-Meier
estimator or the Gray test of the cumulative inci-
dence function (for outcomes with a competing risk)
was used (20). Covariates for the model were selected
on the basis of biological plausibility using directed
acyclic graph analysis to model the hypothesized
relationship between IPC level and MACE to identify
those variables that were potential confounding fac-
tors (21,22). These identiﬁed factors were then used
as covariates for the Cox proportional hazards model
and included a dichotomous variable that indicated
whether the IPC level was above the identiﬁed
threshold by ROC analysis, the diagnosis at time of
enrollment (stable CAD, STEMI, or NSTEMI), initial
treatment (optimal medical therapy alone, stent
placement, or CABG), age, history of heart failure,
smoking, hematocrit, and baseline platelet count. A
p value of <0.05 was considered statistically signiﬁ-
cant. All statistical analyses were done using R for
Statistical Computing version 3.0.0 (R Foundation,
Vienna, Austria). (23).
RESULTS
A total of 95 patients were enrolled in the study
between December 2009 and September 2013. Two
patients (2.1%) withdrew consent after enrollment,
and 4 patients (4.2%) were lost to follow-up despite
at least 3 separate attempts to contact the patient
and/or family with a review of inpatient and outpa-
tient medical records. The remaining 89 patients
(93.7%) were followed up for a median of 31 months
(interquartile range: 10 to 40 months). Baseline
characteristics are shown in Table 1. With the excep-
tion of the platelet assay parameters, there were
no signiﬁcant differences in baseline characteristics
between patients who had MACE at follow-up and
those who did not.
Both the IPC (10,507 vs. 6,322 platelets/ml; p¼0.002)
and the IPF (5.2% vs. 4.1%; p ¼ 0.007) were greater
in patients who had MACE at follow-up (Figure 1).
The total platelet count was higher in patients in the
high IPC tertile compared with those in the interme-
diate and low tertiles (226.2  65.6 vs. 190.1  63.0 vs.
152.2  38.9, respectively; p ¼ 0.001). Follow-up
events in patients in each IPC tertile are shown
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FIGURE 1 Box-and-Whiskers Plot of IPC and IPF Levels,
Stratiﬁed by MACE at Follow-Up
A comparison using Wilcoxon rank sum test shows higher
immature platelet count (IPC) (left; p ¼ 0.002) and immature
platelet fraction (IPF) (right; p ¼ 0.007) in patients with major
adverse cardiovascular events (MACE) at 31 months. Center band
represents median, box hinges represent the ﬁrst and the third
quartiles, and whiskers extend to the most extreme value, which
is no more than 1.5 times the interquartile range from the box
edges.
TABLE 2 Outcome Events Stratiﬁed by IPC Tertile
Total
(N ¼ 89)
IPC Tertile (platelets/ml)
p Value*
Lowest Middle Highest
(1,364–5,836)
(n ¼ 30)
(5,836–9,272)
(n ¼ 29)
(9,272–27,520)
(n ¼ 30)
Death 10 (11.2) 1 (3.3) 3 (10.3) 6 (20) 0.047
NSTEMI 11 (12.4) 1 (3.3) 3 (10.3) 7 (23.3) 0.023
Hospitalization for angina 7 (7.9) 2 (6.7) 1 (3.4) 4 (13.3) 0.175
Revascularization 6 (6.7) 1 (3.3) 1 (3.4) 4 (13.3) 0.116
MACE (composite) 30 (33.7) 5 (16.7) 7 (24.1) 18 (60) <0.001
Values are n (%). *For each tertile, the time to event curves were created and compared using the log-rank
test or Gray’s test (for outcomes where death was a competing risk).
Abbreviations as in Table 1.
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2125in Table 2. At follow-up, 30 patients (33.7%) had
experienced an event at a mean of 10.4  7.9 months
after enrollment. Eleven patients (12.4%) had experi-
enced an NSTEMI, 10 (11.2%) had died, 7 (7.9%) were
hospitalized for chest pain, 6 (6.7%) had undergone
an unplanned revascularization, and 0 had experi-
enced a STEMI. Furthermore, death from cardiovas-
cular causes (advanced heart failure, cardiogenic
shock, or ischemic or arrhythmic death) was reported
in 8 patients. The one death among patients in the
low IPC tertile was attributed to advanced pulmonary
ﬁbrosis. One death among the patients in the high
IPC tertile was attributed to septic shock.
Time-dependent ROC curve analysis demonstrated
an area under the curve (AUC) of 0.774 (Figure 2A).
Further evaluation revealed that a cut point of
7,632 platelets/ml maximized discrimination and was
70.7% sensitive and 82.1% speciﬁc for MACE.
Throughout follow-up, AUC ranged from 0.630 to
0.799, with a median level of 0.746 (Figure 2B). Cox
proportional hazards analysis demonstrated that
even after adjustment for confounding variables,
an IPC level of $7,632 platelets/ml was associated with
an increased risk for MACE (Central Illustration)(hazard ratio [HR]: 4.65; 95% conﬁdence interval [CI]:
1.78 to 12.16; p < 0.002).
There was a modest correlation between IPC and
platelet count (r2 ¼ 0.338) (Figure 3). The perfor-
mances of IPF and IPC in the discrimination of high-
risk patients are compared in Figure 2. Throughout
follow-up, the time-dependent ROC curves for IPC
and IPF were not signiﬁcantly different (Figure 2B),
with the exception of early at 4 months, when IPC had
a higher AUC (73.2% vs. 64.5%; p ¼ 0.044).
DISCUSSION
This is the ﬁrst prospective study to show a rela-
tionship between IPC—a readily available parameter
that can be determined as part of the complete blood
count and is unlikely to be affected by previous
antiplatelet treatment—and clinical events. The rela-
tionship was present even after adjustment for
multiple baseline variables. Additionally, we were
able to detect a cutoff level of IPC with good
discriminative power to predict clinical outcomes
(Central Illustration). IPC, which is easily obtained by
multiplying the IPF by the platelet count, may prove
to be a better tool than IPF, as it incorporates absolute
platelet count as well as the proportion of platelets
that are immature and rich in mRNA.
It is likely that the association we observed
between immature platelets and thromboembolic
events reﬂects the increased ability of immature
platelets to participate in thrombosis compared
with senescent platelets. Hyperactivity of immature
platelets in response to multiple agonists might be, in
part, due to the presence of mRNA (24). Although this
mRNA was at one time considered inconsequential, a
growing body of evidence indicates that spliceosome
complexes are present in platelets, even though they
are anucleate, and that activation-dependent splicing
and translation of pre-mRNA can occur in these
platelets, resulting in the de novo synthesis of
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FIGURE 2 Time-Dependent ROC Curve
(A) Time-dependent receiver-operating characteristic (ROC) curve for IPC (red) and IPF (blue) at 30 months. (B) Time-dependent area under
the curve (AUC) changes over time in months and the 95% conﬁdence interval (solid lines). Abbreviations as in Figure 1.
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2126prothrombotic and proinﬂammatory proteins (25,26).
Mechanistic support for the increased thrombotic
potential of immature platelets is provided by ob-
servations from our laboratory and others of a rela-
tionship between IPC and high residual platelet
reactivity (RPR) despite dual antiplatelet therapy
with aspirin and clopidogrel or with aspirin and pra-
sugrel. This relationship is present in healthy subjects
as well as in patients with CAD (9,10,27,28). Alterna-
tively, as the platelet count is also an acute phase
reactant, an increased IPC may also be a marker of
systemic inﬂammatory activity.
The ﬁndings of the current study expand those
reported by other investigators. Grove et al. (29)
examined the relationship between IPC and high
RPR among patients treated with aspirin and clopi-
dogrel. IPC was reported to reﬂect RPR more precisely
than IPF. When arachidonic acid, collagen, or ADP
was used to induce platelet aggregation, signiﬁcantly
higher IPC levels were found in patients with high
RPR compared with those without high RPR for each
of the agonists. Similar trends were not present for
IPF. Interestingly, the median IPC value that was
associated with RPR in the study by Grove et al. (29)
was 8,400 platelets/ml, which is similar to the cutoff
value of 7,632 platelets/ml observed using ROC curve
analysis in the current study.
Previous cross-sectional studies have reported an
increase in the proportion of immature platelets
in the setting of acute thrombotic events (30,31).
However, in those studies, the measurement ofimmature platelets took place after the event had
occurred, and no longitudinal follow-up was in-
cluded. In the one other longitudinal study that
examined the relationship between immature plate-
lets and clinical events, Cesari et al. (32) reported
that in patients with acute coronary syndromes,
IPF was a predictor of cardiovascular death after
adjustment for the Global Registry of Acute Coronary
Events risk score (odds ratio: 4.15; 95% CI: 1.24 to
13.9; p ¼ 0.02). In comparison, the current study had
a longer follow-up period (31 months), a diverse
composite endpoint (including all-cause mortality),
and adjustment for multiple baseline variables using
a Cox proportional hazards analysis to assess the
relationship between the initial observation and
clinical outcomes.
Given that IPC is the product of the IPF and total
platelet count, it might be expected that the higher
the platelet count, the higher the IPC. However,
we observed only modest correlation between those
2 parameters (r2 ¼ 0.338), perhaps reﬂecting the
persistence of a systemic stimulus for continued
platelet production.
Knowing that patients’ responses to antiplatelet
therapy are not uniform, multiple investigators have
tried to link high RPR to the occurrence of athero-
thrombotic events (33–37). In a study in patients
undergoing drug-eluting stent placement who are
treated with clopidogrel, high RPR was strongly
related to the risk for stent thrombosis (HR: 2.4; 95%
CI: 1.4 to 4.3; p ¼ 0.001), whereas bleeding risk was
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CENTRAL ILLUSTRATION Cox Proportional Hazards Model for MACE at Follow-Up
After adjustment for diagnosis at time of enrollment, initial treatment, age, history of
heart failure, smoking, hematocrit, and platelet count, the level of immature platelet
count (IPC) was found to be signiﬁcantly associated with major adverse cardiovascular
events (MACE).
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FIGURE 3 Scatterplot With Marginal Box-and-Whiskers Plots to Explore
the Relationship Between IPC and Total Platelet Count
The blue line represents linear regression. The Pearson coefﬁcient of determination of 0.338
reﬂects poor correlation between immature platelet count (IPC) and total platelet count.
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2127inversely related to high RPR (HR: 0.73; 95% CI: 0.61
to 0.89; p ¼ 0.02) (38). In our study, when RPR was
evaluated using light transmission aggregometry with
ADP (5 or 20 mM) as the agonist, no signiﬁcant dif-
ference was found between patients who had expe-
rienced an event versus those who did not.
We believe that antiplatelet therapy is shifting into
a new paradigm of personalized therapy. Thus far,
targeting RPR on the basis of aggregometry assays has
not proven to alter clinical outcomes (39–41). The
current data offer a potential new and easily ascer-
tained target for such a strategy. IPC may become an
important tool for investigating personalized anti-
platelet therapy, perhaps by selecting patients who
might be more likely to beneﬁt from drugs with
longer half-lives or from dosing antiplatelet drugs
more frequently than once daily.
STUDY LIMITATIONS. First, the sample size was
small, mainly due to the exclusion of patients who
received blood product transfusions before their
platelet studies. The sample size limited the number
of variables that could be examined to determine
the independence of IPC as a predictor of events, as
well as the robustness of the primary observation.
However, despite the sample size, the observed rela-
tionship between IPC and clinical outcomes was
statistically signiﬁcant. With the number of cova-
riates considered, there was a risk for overﬁtting the
data, which may have limited the model’s predictive
performance.
Second, the design of collecting follow-up infor-
mation via phone calls introduced a potential recall
bias. However, in this study, we conducted a full re-
view of medical records to ensure event accuracy, and
we used a strict deﬁnition of recurrent angina.
Moreover, the fact that hard endpoints (i.e., death,
NSTEMI with biomarker evidence) were driving
the composite endpoint also reduced the effect of
recall bias.
Third, data are lacking as to the stability of the IPC
over the course of time. Such studies are currently
underway.
Finally, the current study does not provide a
mechanistic explanation of the association that was
observed between IPC and clinical outcomes in
patients with CAD. Thus, whether IPC is a modiﬁable
risk marker is still unknown. Platelet count is, in
part, an acute phase reactant, and the proportion
of immature platelets may also increase in response
to a systemic inﬂammatory process. Markers of
inﬂammation were not measured in the current
study. However, the current study demonstrates that
a single measurement of IPC at the point of care may
be a useful predictor of subsequent cardiac events.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Immature platelets are associated with adverse
clinical outcomes in patients with coronary artery
disease.
TRANSLATIONAL OUTLOOK: Better understand-
ing of mechanisms by which immature platelets
escalate risk, such as drug resistance, may aid in
developing more individualized antiplatelet therapy
for prevention of ischemic events.
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2128CONCLUSIONS
IPC is an easily obtained laboratory test that can be
incorporated into a routine complete blood count
with little additional cost and allows for further
stratiﬁcation of patients with CAD in terms of risk
for future MACE. Future studies should focus
on personalizing antiplatelet therapy guided by
IPC level.
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